On #GivingTuesday, the Alzheimer's Drug Discovery Foundation gives thanks to our donors. Because of your generosity, we have been able to advance the most promising ideas to prevent and treat Alzheimer's disease. Since 1998, the ADDF has invested $97 million in critical research and—with your help—we will reach $100 million this year.
Those investments are paying off. Today, we are funding 26 clinical trials,the final stages of a drug's development. In fact, more than 20% of all treatments for Alzheimer's in clinical trials have received support from the ADDF. This includes LM11A-31 from Dr. Frank Longo at Stanford University, which we began funding in 2000 and Time magazine wrote "could change old age." With ADDF support, Dr. Michela Gallagher of Johns Hopkins University is preparing to recruit patients for a phase 3 trial of AGB-101, a drug that could prevent mild cognitive impairment from progressing to Alzheimer's disease. And at Oryzon Genomics in Spain, Dr. Tamara Maes is developing ORY-2001, the first epigenetic drug for Alzheimer's to ever reach the clinic.
Thanks to you, we are closer than we've ever been to a world in which no one suffers from Alzheimer's disease.
|HELP CONQUER ALZHEIMER'S|